Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy

SIMPLE SUMMARY: Despite the variety of drugs used to treat multiple myeloma and the ever-lengthening survival times, a recurring problem is that many current drugs affect healthy cells, causing side effects, additional illnesses, and drug intolerances. In theory, antibody-drug conjugates targeting d...

Descripción completa

Detalles Bibliográficos
Autores principales: Xing, Lijie, Liu, Yuntong, Liu, Jiye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137208/
https://www.ncbi.nlm.nih.gov/pubmed/37190168
http://dx.doi.org/10.3390/cancers15082240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137208/
https://www.ncbi.nlm.nih.gov/pubmed/37190168
http://dx.doi.org/10.3390/cancers15082240

Ejemplares similares